



**Bortezomib (Velcade®)**

**Revision: 2**

**Policy Number: M-0014**

**Last Update: 6/4/2014**

Payment will not be made for any use of these drugs outside of the criteria without prior authorization. The member may not be billed unless the member explicitly agrees in writing to be responsible for the charges in accordance with the contract/provider manual. Prior authorization will only be given if the provider demonstrates the intended use meets Medicare coverage guidelines.

When appropriate compendia references the use of one of the chemotherapeutic agents listed in this Article as part of a 'combination therapy', the drug is only approved for use in such 'combinations', and the documentation should reflect, and be specific about, the use of the additional 'combination therapy' drugs.

**Coverage Guidelines:**

FDA Indications

- Mantle cell lymphoma, In patients who have received at least 1 prior therapy
- Multiple myeloma

Off Labeled Indications

- Waldenström macroglobulinemia

**Coding Information:**

HCPCS Code(s)

|       |                               |
|-------|-------------------------------|
| J9041 | INJECTION, BORTEZOMIB, 0.1 MG |
|-------|-------------------------------|

ICD-9 Code(s)

|                   |  |
|-------------------|--|
| 200.40-<br>200.48 | MANTLE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES - MANTLE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES   |
| 200.80-<br>200.88 | OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA UNSPECIFIED SITE - OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES |
| 202.80-           | OTHER MALIGNANT LYMPHOMAS UNSPECIFIED SITE - OTHER MALIGNANT   |



|                   |  |
|-------------------|--|
| 202.88            | LYMPHOMAS INVOLVING LYMPH NODES OF MULTIPLE SITES  |
| 203.00-<br>203.02 | MULTIPLE MYELOMA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION -<br>MULTIPLE MYELOMA, IN RELAPSE                                       |
| 203.10            | PLASMA CELL LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION   |
| 203.12            | PLASMA CELL LEUKEMIA, IN RELAPSE   |
| 203.80-<br>203.82 | OTHER IMMUNOPROLIFERATIVE NEOPLASMS, WITHOUT MENTION OF HAVING<br>ACHIEVED REMISSION - OTHER IMMUNOPROLIFERATIVE NEOPLASMS, IN RELAPSE |
| 238.6             | NEOPLASM OF UNCERTAIN BEHAVIOR OF PLASMA CELLS   |
| 273.3             | MACROGLOBULINEMIA  |

**Background:**

Velcade is a potent and selective inhibitor of the proteasome, a multicatalytic enzyme that mediates many cellular regulatory signals by degrading regulatory proteins or their inhibitors.

**Definitions:**

HCPCS Code—Healthcare Common Procedure Coding System - A system of letter and number codes assigned to procedures, medications, supplies and equipment used for pricing and billing.

ICD-9 Code—International Classification of Disease, 9<sup>th</sup> edition. A standardized classification of disease, injuries, and causes of death, by etiology and anatomic localization and codified into a 6-digit number, which allows clinicians, statisticians, politicians, health planners and others to speak a common language, both US and internationally.

Proteasome inhibitors—drugs that block the action of proteasomes, cellular complexes that break down proteins

**References:**

1. Velcade [package insert]. Cambridge, MA: Millennium, Inc.; 2012. Available at: [http://www.velcade.com/Files/PDFs/VELCADE\\_PRESCRIBING\\_INFORMATION.pdf](http://www.velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf) Accessed May 29, 2012.
2. The NCCN Drugs & Biologics Compendium™ © 2010 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed May 25, 2012.
3. Local Coverage Article for Drugs and Biologics – Chemotherapeutic Agents (A48896) (R4). Available at: <http://www.cms.gov/medicare-coverage-database/details/article->



[details.aspx?articleId=48896&ver=89&ContrId=213&ContrVer=1&CtrctrSelected=213\\*1&Date=01%2f01%2f2013&DocId=A48896&bc=hAAAAAgAEAAAAA%3d%3d&](http://www.vivaprovider.com/Details.aspx?articleId=48896&ver=89&ContrId=213&ContrVer=1&CtrctrSelected=213*1&Date=01%2f01%2f2013&DocId=A48896&bc=hAAAAAgAEAAAAA%3d%3d&). Accessed June 4, 2014.

4. Micromedex<sup>®</sup> 2.0. Velcade. Available at: [http://www.thomsonhc.com/micromedex2/librarian/ND\\_T/evidencexpert/ND\\_PR/evidencexpert/CS/584883/ND\\_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/BA2716/ND\\_PG/evidencexpert/ND\\_B/evidencexpert/ND\\_P/evidencexpert/PFActionId/evidencexpert.DisplayDrugpointDocument?docId=927753&contentSetId=100&title=Bortezomib&servicesTitle=Bortezomib&topicId=dosingAndIndicationsSection&subtopicId=nonfdaSection](http://www.thomsonhc.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/584883/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/BA2716/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.DisplayDrugpointDocument?docId=927753&contentSetId=100&title=Bortezomib&servicesTitle=Bortezomib&topicId=dosingAndIndicationsSection&subtopicId=nonfdaSection). Accessed May 29, 2012.

**Document History:**

Date Written: 5/29/12

Effective Date: 4/1/13

Revision 1: 3/19/2013

Revision 2: 6/4/2014

Internal Review: 6/11/2014

External Review: 6/17/2014

For the Archived Policy, please go

to <http://www.vivaprovider.com/Resources/CoveragePolicies.aspx> and click on the Archived Policies Link.